These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
310 related articles for article (PubMed ID: 22469864)
1. Immunogenicity and specificity of norovirus Consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations. Parra GI; Bok K; Taylor R; Haynes JR; Sosnovtsev SV; Richardson C; Green KY Vaccine; 2012 May; 30(24):3580-6. PubMed ID: 22469864 [TBL] [Abstract][Full Text] [Related]
2. A bivalent virus-like particle based vaccine induces a balanced antibody response against both enterovirus 71 and norovirus in mice. Wang X; Ku Z; Dai W; Chen T; Ye X; Zhang C; Zhang Y; Liu Q; Jin X; Huang Z Vaccine; 2015 Oct; 33(43):5779-5785. PubMed ID: 26424606 [TBL] [Abstract][Full Text] [Related]
3. Simultaneous Immunization with Multivalent Norovirus VLPs Induces Better Protective Immune Responses to Norovirus Than Sequential Immunization. Malm M; Vesikari T; Blazevic V Viruses; 2019 Nov; 11(11):. PubMed ID: 31684058 [TBL] [Abstract][Full Text] [Related]
5. Broad blockade antibody responses in human volunteers after immunization with a multivalent norovirus VLP candidate vaccine: immunological analyses from a phase I clinical trial. Lindesmith LC; Ferris MT; Mullan CW; Ferreira J; Debbink K; Swanstrom J; Richardson C; Goodwin RR; Baehner F; Mendelman PM; Bargatze RF; Baric RS PLoS Med; 2015 Mar; 12(3):e1001807. PubMed ID: 25803642 [TBL] [Abstract][Full Text] [Related]
6. Functionality and avidity of norovirus-specific antibodies and T cells induced by GII.4 virus-like particles alone or co-administered with different genotypes. Malm M; Tamminen K; Heinimäki S; Vesikari T; Blazevic V Vaccine; 2018 Jan; 36(4):484-490. PubMed ID: 29246474 [TBL] [Abstract][Full Text] [Related]
7. Norovirus GII.17 Virus-Like Particles Bind to Different Histo-Blood Group Antigens and Cross-React with Genogroup II-Specific Mouse Sera. Malm M; Tamminen K; Vesikari T; Blazevic V Viral Immunol; 2018 Dec; 31(10):649-657. PubMed ID: 30431404 [TBL] [Abstract][Full Text] [Related]
8. Robust mucosal-homing antibody-secreting B cell responses induced by intramuscular administration of adjuvanted bivalent human norovirus-like particle vaccine. Sundararajan A; Sangster MY; Frey S; Atmar RL; Chen WH; Ferreira J; Bargatze R; Mendelman PM; Treanor JJ; Topham DJ Vaccine; 2015 Jan; 33(4):568-76. PubMed ID: 25444793 [TBL] [Abstract][Full Text] [Related]
9. The endemic GII.4 norovirus-like-particle induced-antibody lacks of cross-reactivity against the epidemic GII.17 strain. Du J; Gu Q; Liu Y; Li Q; Guo T; Liu Y J Med Virol; 2021 Jun; 93(6):3974-3979. PubMed ID: 32869863 [TBL] [Abstract][Full Text] [Related]
10. Identification and characterization of antibody-binding epitopes on the norovirus GII.3 capsid. Mahar JE; Donker NC; Bok K; Talbo GH; Green KY; Kirkwood CD J Virol; 2014 Feb; 88(4):1942-52. PubMed ID: 24284328 [TBL] [Abstract][Full Text] [Related]
11. A novel intramuscular bivalent norovirus virus-like particle vaccine candidate--reactogenicity, safety, and immunogenicity in a phase 1 trial in healthy adults. Treanor JJ; Atmar RL; Frey SE; Gormley R; Chen WH; Ferreira J; Goodwin R; Borkowski A; Clemens R; Mendelman PM J Infect Dis; 2014 Dec; 210(11):1763-71. PubMed ID: 24951828 [TBL] [Abstract][Full Text] [Related]
12. Norovirus VLPs and rotavirus VP6 protein as combined vaccine for childhood gastroenteritis. Blazevic V; Lappalainen S; Nurminen K; Huhti L; Vesikari T Vaccine; 2011 Oct; 29(45):8126-33. PubMed ID: 21854823 [TBL] [Abstract][Full Text] [Related]